What’s new

• GLP-1 market share estimate halved to 5% from the 10% claimed in February.
• FY26 MedTech acquisition count corrected to three from the four previously reported.
• FY27 guidance targets 23% revenue growth and a 5% EBITDA margin.

Why it matters

Management credibility suffers when basic operational metrics like acquisition counts and market share estimates are revised downward shortly after being reported. These discrepancies suggest a lack of precision in internal reporting that requires close monitoring.

What we’re watching

• Whether the 5% EBITDA margin target is met in FY27.
• The sustainability of the 50% EBITDA-to-operating cash flow conversion goal.
• Any further revisions to historical operational data.

The full read

Entero Healthcare’s post-results conference call left investors with a mix of ambitious targets and uncomfortable corrections. Management guided for 23% revenue growth and a 5% EBITDA margin in FY27, while promising a 50% conversion of EBITDA to operating cash flow. The session included two material revisions to prior claims. The company halved its GLP-1 market share estimate to 5% from the 10% cited in February and admitted it closed only three MedTech acquisitions in FY26, not the four previously stated. These inconsistencies raise questions about the accuracy of internal reporting. Management pointed to a network of 100,000 retail pharmacy customers and 3,300 manufacturer partners, but the focus remains on whether the ₹1,000 crore annualised run-rate in the MedTech segment can deliver the promised margins. With ROCE rising to 14.6% from 10.7%, the operational performance is improving, but the accuracy of the reported data is now the primary test.

Primary source: BSE · NSE

What’s new

• FY26 revenue climbed 29.6% to ₹6,591 crore.
• Profit after tax rose 35.6% to ₹146 crore.
• The board approved the acquisition of two surgical distribution firms for ₹9.21 crore.

Why it matters

These results track with the company's established growth trajectory. The acquisition of two surgical distribution firms is immaterial relative to the company's ₹5,887 crore market cap.

What we’re watching

• Whether the company maintains this growth pace in FY27.
• Integration progress of the newly acquired distribution assets.
• Future capital allocation beyond small bolt-on deals.

The full read

Entero Healthcare delivered 29.6% revenue growth in FY26, reaching ₹6,591 crore. Profit after tax grew 35.6% to ₹146 crore.

These results align with the company's existing trajectory and offer no surprises for the market. Alongside the financial release, the board approved the acquisition of two surgical distribution firms for a total consideration of up to ₹9.21 crore. Given the company's ₹5,887 crore market capitalization, this deal is immaterial.

Routine.

Other board outcomes, including director reappointments and ESOP grants, are purely procedural. The filing confirms the company's current scale but introduces no new tradeable information for investors to digest.

Primary source: BSE · NSE

What’s new

• FY26 revenue reached ₹6,591 crore, up 29.6%.
• Profit after tax climbed 35.6% to ₹146 crore.
• The board approved a small bolt-on acquisition of two surgical distribution firms for ₹9.21 crore.

Why it matters

These results confirm the company's ongoing growth trajectory through both organic and inorganic channels. The latest acquisition is immaterial to the company's ₹5,887 crore market cap, serving as a routine addition rather than a shift in strategy.

What we’re watching

• Integration progress of the newly acquired surgical distribution firms.
• Sustainability of the 35.6% profit growth rate in the coming fiscal year.
• Any further M&A activity to expand the distribution footprint.

The full read

Entero Healthcare Solutions closed FY26 with consolidated revenue of ₹6,591 crore, a 29.6% increase over the previous year. Profit after tax rose 35.6% to ₹146 crore, reflecting the company's reliance on both organic growth and acquisitions.

It is a steady performance.

Alongside these financial results, the board approved the purchase of two surgical distribution firms for a total of ₹9.21 crore, an acquisition that remains entirely immaterial given the company's ₹5,887 crore market capitalization. The filing also contained standard procedural items, including director reappointments and ESOP grants, which provide no new tradeable information for the market.

Primary source: BSE · NSE

What’s new

• FY26 revenue reached ₹6,591 crore, up 29.6% year-on-year.
• Profit after tax climbed 35.6% to ₹146 crore.
• The board approved the acquisition of two surgical distribution firms for ₹9.2 crore.

Why it matters

The results show consistent growth driven by both organic expansion and acquisitions. The latest bolt-on deal is immaterial to the company's ₹5,887 crore market cap, confirming this is a routine disclosure of expected financial performance.

What we’re watching

• Integration progress of the newly acquired surgical distribution firms.
• Sustainability of the 35.6% profit growth rate in the coming year.
• Future acquisition pipeline given the company's inorganic growth strategy.

The full read

Entero Healthcare Solutions closed FY26 with consolidated revenue of ₹6,591 crore, a 29.6% increase over the prior year. Profit after tax grew by 35.6% to ₹146 crore, reflecting the company's ongoing reliance on both organic growth and acquisitions.

It is steady work.

Alongside the financial results, the board approved the purchase of two surgical distribution firms for a total of ₹9.2 crore. Given the company's market cap of ₹5,887 crore, this deal is immaterial, and the filing also covered routine governance items including director reappointments and ESOP grants that offer no surprises for investors.

Primary source: BSE · NSE